Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials
| Autor: | Alan G Wade, Raymond W. Lam, Henning F. Andersen |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
medicine.medical_specialty
Venlafaxine Thiophenes Citalopram Duloxetine Hydrochloride Gastroenterology chemistry.chemical_compound Internal medicine mental disorders medicine Humans Duloxetine Escitalopram Pharmacology (medical) Psychiatry Randomized Controlled Trials as Topic Depressive Disorder Major Adrenergic Uptake Inhibitors Antidepressive Agents Psychiatry and Mental health Tolerability chemistry Montgomery–Åsberg Depression Rating Scale Clinical Global Impression Psychology Reuptake inhibitor Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | International Clinical Psychopharmacology. 23:181-187 |
| ISSN: | 0268-1315 |
| Popis: | Pooled analyses have shown that escitalopram has superior effectiveness versus all comparators, including selective serotonin reuptake inhibitors and venlafaxine. Recent studies have compared escitalopram with duloxetine. Data from two randomized, double-blind studies that compared escitalopram (10-20 mg/day) and duloxetine (60 mg/day) were pooled and analysed for all patients and for the subsample of severely depressed patients [baseline Montgomery-Asberg Depression Rating Scale (MADRS) score > or =30]. Escitalopram (n=280) was superior to duloxetine (n=284) with respect to mean change from baseline in MADRS score at weeks 1, 2, 4 and 8 with a mean treatment difference at week 8 of 2.6 points (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|